JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms

References

• Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am. J. Hematol.47(2), 89–93 (1994).
   PubMed Web of Science ®Google Scholar
• Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. Am. J. Hematol.61(1), 10–15 (1999).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia22(1), 14–22 (2008).
   PubMed Web of Science ®Google Scholar
• Dameshek W. Some speculations on the myeloproliferative syndromes. Blood6(4), 372–375 (1951).
   PubMed Web of Science ®Google Scholar
• Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem- cell and probable clonal origin of the disease. N. Engl. J. Med.295(17), 913–916 (1976).
   PubMed Web of Science ®Google Scholar
• Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood58(5), 916–919 (1981).
   PubMed Web of Science ®Google Scholar
• Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood51(2), 189–194 (1978).
   PubMed Web of Science ®Google Scholar
• Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N. Engl. J. Med.290(24), 1382 (1974).
   PubMed Web of Science ®Google Scholar
• el Kassar N, Hetet G, Li Y, Briere J, Grandchamp B. Clonal analysis of haemopoietic cells in essential thrombocythaemia. Br. J. Haematol.90(1), 131–137 (1995).
   PubMed Web of Science ®Google Scholar
• Tsukamoto N, Morita K, Maehara T et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br. J. Haematol.86(2), 253–258 (1994).
   PubMed Web of Science ®Google Scholar
• Dai CH, Krantz SB, Dessypris EN, Means RT, Horn ST, Gilbert HS. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte–macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte–macrophage colony-stimulating factor. Blood80(4), 891–899 (1992).
   PubMed Web of Science ®Google Scholar
• Dai CH, Krantz SB, Means RT, Horn ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J. Clin. Invest.87(2), 391–396 (1991).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle6(5), 550–566 (2007).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell93(3), 397–409 (1998).
   PubMed Web of Science ®Google Scholar
• Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell93(3), 385–395 (1998).
   PubMed Web of Science ®Google Scholar
• Ihle J, Gilliland D. Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Develop.17(1), 8–14 (2007).
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene285(1–2), 1–24 (2002).
   PubMed Web of Science ®Google Scholar
• Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol.71(6), 713–721 (2006).
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N. Engl. J. Med.338(9), 572–580 (1998).
   PubMed Web of Science ®Google Scholar
• Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with polycythemia rubra vera. Experiment. Hematol.29(6), 694–702 (2001).
   PubMed Web of Science ®Google Scholar
• Komura E, Chagraoui H, Mansat de Mas V et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Experiment. Hematol.31(7), 622–630 (2003).
   PubMedGoogle Scholar
• Ugo V, Marzac C, Teyssandier I et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Experiment. Hematol.32(2), 179–187 (2004).
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet365(9464), 1054–1061 (2005).
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature434(7037), 1144–1148 (2005).
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med.352(17), 1779–1790 (2005).
   PubMed Web of Science ®Google Scholar
• Levine R, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell7(4), 387–397 (2005).
   PubMed Web of Science ®Google Scholar
• Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experiment. Hematol.30(3), 229–236 (2002).
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk. Lymphoma49(3), 388–397 (2008).
   PubMed Web of Science ®Google Scholar
• Levine R, Wernig G. Role of JAK–STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am. Soc. Hematol. Educ. Program.233–239, 510 (2006).
   Google Scholar
• Bumm T, Elsea C, Corbin A et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res.66(23), 11156–11165 (2006).
   PubMed Web of Science ®Google Scholar
• Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood108(5), 1652–1660 (2006).
   PubMed Web of Science ®Google Scholar
• Shide K, Shimoda H, Kumano T et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2V617F. Leukemia22(1), 87–95 (2008).
   PubMed Web of Science ®Google Scholar
• Tiedt R, Hao-Shen H, Sobas MA et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood111(8), 3931–3940 (2008).
   PubMed Web of Science ®Google Scholar
• Xing S, Wanting T, Zhao W et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood111(10), 5109–5117 (2008).
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia22(7), 1299–1307 (2008).
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Poli G et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica93(1), 41–48 (2008).
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Antonioli E, Guglielmelli P et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia21(9), 1952–1959 (2007).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Strand J, Lasho T et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia21(9), 2074–2075 (2007).
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson R, Lasho T et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer109(11), 2279–2284 (2007).
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Griesshammer M, Döhner K et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood107(5), 2098–2100 (2006).
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Barosi G, Specchia G et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood114(8), 1477–1483 (2009).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho T, Huang J et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia22(4), 756–761 (2008).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho T, Schwager SM et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br. J. Haematol.131(3), 320–328 (2005).
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Tonetti C et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood109(1), 71–77 (2007).
   PubMed Web of Science ®Google Scholar
• Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood108(9), 3128–3134 (2006).
   PubMed Web of Science ®Google Scholar
• Larsen TS, Christensen J, Hasselbalch H, Pallisgaard N. The JAK2V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br. J. Haematol.136(5), 745–751 (2007).
   PubMed Web of Science ®Google Scholar
• Jamieson CH, Gotlib J, Durocher JA et al. The JAK2V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl Acad. Sci. USA103(16), 6224–6229 (2006).
   PubMed Web of Science ®Google Scholar
• James C, Mazurier F, Dupont S et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood112(6), 2429–2438 (2008).
   PubMedGoogle Scholar
• Wernig G, Mercher T, Okabe R, Levine R, Lee BH, Gilliland DG. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood107(11), 4274–4281 (2006).
   PubMed Web of Science ®Google Scholar
• Zaleskas V, Krause DS, Lazarides K et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE1(1), e18 (2006).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood111(5), 2785–2789 (2008).
   PubMedGoogle Scholar
• Jones AV, Chase A, Silver RT et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet.41(4), 446–449 (2009).
   PubMed Web of Science ®Google Scholar
• Kilpivaara O, Mukherjee S, Schram AM et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nat. Genet.41(4), 455–459 (2009).
   PubMed Web of Science ®Google Scholar
• Olcaydu D, Harutyunyan A, Jager R et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet.41(4), 450–454 (2009).
   PubMed Web of Science ®Google Scholar
• Campbell P, Baxter E, Beer P et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood108(10), 3548–3555 (2006).
   PubMed Web of Science ®Google Scholar
• Theocharides A, Boissinot M, Girodon F et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood110(1), 375–379 (2007).
   PubMed Web of Science ®Google Scholar
• Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood108(7), 2435–2437 (2006).
   PubMed Web of Science ®Google Scholar
• Nussenzveig RH, Swierczek SI, Jelinek J et al. Polycythemia vera is not initiated by JAK2V617F mutation. Experiment. Hematol.35(1), 32–38 (2007).
   PubMed Web of Science ®Google Scholar
• Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood114(14), 3018–3023 (2009).
   PubMed Web of Science ®Google Scholar
• Dupont S, Masse A, James C et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood110(3), 1013–1021 (2007).
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med.360(22), 2289–2301 (2009).
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Mullally A, Hedvat C et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood114(1), 144–147 (2009).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A, Lim KH et al.TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia23(5), 905–911 (2009).
   PubMed Web of Science ®Google Scholar
• Viguié F, Aboura A, Bouscary D et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia19(8), 1411–1415 (2005).
   Google Scholar
• Abdel-Wahab O, Manshouri T, Patel J et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res.70(2), 447–452 (2010).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lim KH, Abdel-Wahab O et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia23(7), 1343–1345 (2009).
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Tiu RV et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood113(25), 6403–6410 (2009).
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet.41(7), 838–842 (2009).
   PubMed Web of Science ®Google Scholar
• Mohamedali AM, Smith AE, Gaken J et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J. Clin. Oncol.27(24), 4002–4006 (2009).
   PubMedGoogle Scholar
• Tefferi A, Levine RL, Lim KH et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia23(5), 900–904 (2009).
   PubMed Web of Science ®Google Scholar
• Lorsbach R, Moore J, Mathew S, Raimondi S, Mukatira S, Downing J. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia17(3), 637–641 (2003).
   PubMed Web of Science ®Google Scholar
• Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res.62(14), 4075–4080 (2002).
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science324(5929), 930–935 (2009).
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine R et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med.356(5), 459–468 (2007).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho T, Finke C, Hanson C, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia21(9), 1960–1963 (2007).
   PubMed Web of Science ®Google Scholar
• Pietra D, Li S, Brisci A et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood111(3), 1686–1689 (2008).
   PubMed Web of Science ®Google Scholar
• Wang Y, Vandris K, Jones A et al.JAK2 Mutations are present in all cases of polycythemia vera. Leukemia22(6), 1289–1289 (2008).
   PubMed Web of Science ®Google Scholar
• Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood89(12), 4628–4635 (1997).
   PubMed Web of Science ®Google Scholar
• Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood90(5), 2057–2061 (1997).
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med.3(7), e270 (2006).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Levine R, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108(10), 3472–3476 (2006).
   PubMed Web of Science ®Google Scholar
• Croker B, Kiu H, Nicholson S. SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol.19(4), 414–422 (2008).
   PubMed Web of Science ®Google Scholar
• O’Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the JAK–STAT–SOCS pathway in disease. Mol. Immunol.44(10), 2497–2506 (2007).
   PubMed Web of Science ®Google Scholar
• Endo TA, Masuhara M, Yokouchi M et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature387(6636), 921–924 (1997).
   PubMed Web of Science ®Google Scholar
• Sasaki A, Yasukawa H, Suzuki A et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells4(6), 339–351 (1999).
   PubMed Web of Science ®Google Scholar
• Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. SOCS-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell Biol.21(10), 3547–3557 (2001).
   PubMedGoogle Scholar
• Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. Regulation of JAK2 through the ubiquitin–proteasome pathway involves phosphorylation of JAK2 on Y1007 and interaction with SOCS-1. Mol. Cell Biol.22(10), 3316–3326 (2002).
   PubMed Web of Science ®Google Scholar
• Hortner M, Nielsch U, Mayr LM, Heinrich PC, Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur. J. Biochem.269(10), 2516–2526 (2002).
   PubMedGoogle Scholar
• Capello D, Deambrogi C, Rossi D et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br. J. Haematol.141(4), 504–511 (2008).
   PubMed Web of Science ®Google Scholar
• Jost E, do O N, Dahl E et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia21(3), 505–510 (2007).
   PubMed Web of Science ®Google Scholar
• Teofili L, Martini M, Cenci T et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int. J. Cancer123(7), 1586–1592 (2008).
   PubMed Web of Science ®Google Scholar
• Quentmeier H, Geffers R, Jost E et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia22(12), 2169–2175 (2008).
   PubMedGoogle Scholar
• Haan S, Ferguson P, Sommer U et al. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J. Biol. Chem.278(34), 31972–31979 (2003).
   PubMedGoogle Scholar
• Hookham M, Elliott J, Suessmuth Y et al. The myeloproliferative disorder associated JAK2V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood109(11), 4924–4929 (2007).
   PubMedGoogle Scholar
• Rudd CE. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci. STKE2001(85), PE1 (2001).
   Google Scholar
• Takaki S, Sauer K, Iritani BM et al. Control of B cell production by the adaptor protein lnk. Definition of a conserved family of signal-modulating proteins. Immunity13(5), 599–609 (2000).
   PubMed Web of Science ®Google Scholar
• Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J. Exp. Med.195(2), 151–160 (2002).
   PubMed Web of Science ®Google Scholar
• Velazquez L, Cheng AM, Fleming HE et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J. Exp. Med.195(12), 1599–1611 (2002).
   PubMed Web of Science ®Google Scholar
• Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J. Exp. Med.200(5), 569–580 (2004).
   PubMed Web of Science ®Google Scholar
• Buza-Vidas N, Antonchuk J, Qian H et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev.20(15), 2018–2023 (2006).
   PubMed Web of Science ®Google Scholar
• Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood105(12), 4604–4612 (2005).
   PubMed Web of Science ®Google Scholar
• Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J. Clin. Invest.118(8), 2832–2844 (2008).
   PubMed Web of Science ®Google Scholar
• Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler HP. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood110(9), 3360–3364 (2007).
   PubMed Web of Science ®Google Scholar
• Simon C, Dondi E, Chaix A et al. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood112(10), 4039–4047 (2008).
   PubMedGoogle Scholar
• Oh ST, Simonds EF, Jones C et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK–STAT signaling in patients with myeloproliferative neoplasms. Blood DOI: blood-2010-02-270108 (2010) (Epub ahead of print).
   Google Scholar
• Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat. Rev. Mol. Cell Biol.6(12), 907–918 (2005).
   PubMed Web of Science ®Google Scholar
• Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC 3rd. v-Cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc. Natl Acad. Sci. USA86(4), 1168–1172 (1989).
   PubMed Web of Science ®Google Scholar
• Caligiuri MA, Briesewitz R, Yu J et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood110(3), 1022–1024 (2007).
   PubMed Web of Science ®Google Scholar
• Sargin B, Choudhary C, Crosetto N et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood110(3), 1004–1012 (2007).
   PubMed Web of Science ®Google Scholar
• Dunbar AJ, Gondek LP, O’Keefe CL et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res.68(24), 10349–10357 (2008).
   PubMed Web of Science ®Google Scholar
• Grand FH, Hidalgo-Curtis CE, Ernst T et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood113(24), 6182–6192 (2009).
   PubMed Web of Science ®Google Scholar
• Makishima H, Cazzolli H, Szpurka H et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol.27(36), 6109–6116 (2009).
   PubMed Web of Science ®Google Scholar
• Sanada M, Suzuki T, Shih LY et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature460(7257), 904–908 (2009).
   PubMed Web of Science ®Google Scholar
• Loh ML, Sakai DS, Flotho C et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood114(9), 1859–1863 (2009).
   PubMed Web of Science ®Google Scholar
• Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernández-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med.338(9), 564–571 (1998).
   PubMed Web of Science ®Google Scholar
• Plo I, Nakatake M, Malivert L et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood112(4), 1402–1412 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao R, Oxley D, Smith T, Follows GA, Green AR, Alexander DR. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol.5(1), e1 (2007).
   Google Scholar
• Zhao R, Follows GA, Beer PA et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N. Engl. J. Med.359(26), 2778–2789 (2008).
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N. Engl. J. Med.362(4), 369–370 (2010).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke CM et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia DOI: 10.1038/leu.2010.77 (2010) (Epub ahead of print).
   Google Scholar
• Jager R, Gisslinger H, Berg T et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms at transformation to acute myeloid leukemia. Blood114, 181 (2009) (Abstract 435).
   Google Scholar
• Mullighan CG, Miller CB, Radtke I et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature453(7191), 110–114 (2008).
   PubMed Web of Science ®Google Scholar
• Jamieson CH, Ailles LE, Dylla SJ et al. Granulocyte–macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med.351(7), 657–667 (2004).
   PubMed Web of Science ®Google Scholar
• Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer7(9), 673–683 (2007).
   PubMed Web of Science ®Google Scholar